New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
08:08 EDTHSICHenry Schein price target raised to $98 from $92 at RW Baird
Baird raised its price target on Henry Schein following solid Q4 results. The firm believes guidance is conservative as they expect another good year due citing tailwinds from IDS in Germany, share repurchases, and sell through of lower priced Q4 inventory at 2013 prices. Shares are Outperform rated.
News For HSIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
09:02 EDTHSIC3D Systems, Henry Schein announce multi-national distribution agreement
Subscribe for More Information
February 26, 2015
10:45 EDTHSICHenry Schein Medical to offer Atossa Genetics' FullCYTE Breast Aspirator
Earlier today, Atossa Genetics (ATOS) announced that Henry Schein Medical, the U.S. Medical business of Henry Schein (HSIC), will offer its customers the FullCYTE Breast Aspirator. The Atossa FullCYTE Breast Aspirator is used by OB/GYNs, primary care physicians and women's clinics to collect fluid from breasts for subsequent cytological evaluation. Dr. Steven C. Quay, Chairman, President & CEO of Atossa Genetics, commented, "Working with Henry Schein is an important step forward in making the FullCYTE Breast Aspirator available nationwide. Henry Schein is an industry leader and its multi-channel sales organization allows for expanded reach into multiple market segments within health care for our device. We are thrilled to work with a company such as Henry Schein and believe our arrangement will contribute positively to our upcoming nationwide launch." Shares of Atossa Genetics are up almost 48% in morning trading.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use